返回 Agenda
Hepatitis C: Expensive Cure Versus Life-Long Suffering and Health Care Expenses
Session Chair(s)
Helga Ruebsamen-Schaeff
Chair of the Board
AiCuris, Germany
Since HCV increases the risk of liver cirrhosis and liver cancer tremendously, it was a great achievement that the industry was able, only about 24 years after the discovery of the virus to develop drugs which cure the disease. Yet, the prices which were asked for such curative drugs were heavily criticized. The panel will discuss how a fair price for a curative treatment can be defined and how it can be avoided that price cuts make an indication area so unattractive that nearly no new drugs are being developed any more, as is the case for antibiotics.